1Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure [ J ]. J Am Coil Cardiol,2007,49(2) : 171-180.
4Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardio- vascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease [ J ]. Circulation, 2003, 107 ( 11 ): 1514-1519.
5da Cunha V, Tham DM, Martin-Mc- Nuity B, et al. Enalapril attenuates angiotensin Ⅱ-induced atherosclerosis and vascular inflammation [ J ]. Atherosclerosis ,2005,178 ( 1 ) :9-17.
8Willenheimer R, Helmers C, Pantev E, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients [ J ]. Int J Cardiol, 2002,85 ( 2/3 ) : 261-270.
9Mancini GB.The 'double dip' hypoth- esis: simultaneous prevention of car- diovascular and pulmonary morbidity and mortality using angiotensin Ⅱ type 1 receptor blockers [ J ]. Can J Cardio1,2005,21 (6) :519-523.
5Padeletti M,Jelic S,Lejemtel TH.Coexistent chronic obstructive pulmonary disease and heart failure in the elderly[J].Int J Cardiol,2008,125 (2):209-215.
6The Heart Failure Society of America.Executive summary:HFSA 2006 comprehensive heart failure practice guideline[J].J Card Fail,2006,12 (1):10-38.
7Pauwels RA,Buist AS,Ma P,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease:National Heart,Lung,and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD):executive summary[J].Respir Care,2001,46 (8):798-825.
9Drechsler K,Dietz R,Klein H,et al.Euro heart failure survey.Medical treatment not in line with current guidelines[J].Z Kardiol,2005,94 (8):510-515.
10Holguin F,Folch E,Redd SC,et al.Comorbidity and mortality in COPD-related hospitalizations in the United States,1979 to 2001[J].Chest,2005,128 (4):2005-2011.
